Pediatric (PARDS) and neonatal (NARDS) acute respiratory distress syndrome have
different age-specific characteristics and definitions. Trials on surfactant for ARDS in children …

Objective To provide the best clinical practice guidance for surfactant use in preterm
neonates with respiratory distress syndrome (RDS). The RDS-Neonatal Expert Taskforce …

Background There are no evidence-based recommendations for surfactant use in late
preterm (LPT) and term infants with respiratory distress syndrome (RDS). Objective To …

Exogenous surfactant therapy has been part of the routine care of preterm neonates with
respiratory distress syndrome (RDS) since the beginning of the 1990s. Discoveries that led …

There is a lack of definitive data on the effective management of acute respiratory distress
syndrome (ARDS) in infants and children. The development and validation of the Berlin …

Background: Clinical trials have confirmed that surfactant therapy is effective in improving
the immediate need for respiratory support and the clinical outcome of premature newborns …

Exogenous surfactants have been used as an effective treatment of neonatal respiratory
distress syndrome (RDS). Different preparations of surfactant carry different biophysical and …

Purpose. The aim of this prospectively designed study was to investigate the efficacy of
surfactant (S) for acute respiratory distress syndrome (ARDS) in children. Materials and …

Surfactant whether given prophylactically in the delivery room or to babies with established
respiratory distress syndrome (RDS) reduces the severity of RDS, incidence of air leaks and …

Surfactant treatment is standard of care for infants who have respiratory distress syndrome
(RDS). However, many practical questions remain about what RDS is, and who should be …